Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...

Gilead Sciences has signed its third acquisition deal since the start of the year, agreeing to buy Germany's Tubulis and its pipeline of antibody-drug conjugates (ADCs) for cancer. Assuming the ...

HHS Secretary Robert F Kennedy Jr has followed a court ruling that his controversial appointments to the CDC's Advisory Committee on Immunization Practices (ACIP) were unlawful by changing the panel's ...

Anthropic has continued its push into the healthcare sector by acquiring New York startup Coefficient Bio, a specialist in applying AI to drug discovery that was set up last year but until now has ...

Lunsekimig is one of a trio of clinical candidates that Sanofi is developing as successors to its big-selling IL-3 and IL-13 ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Neurocrine Biosciences has agreed a $2.9 billion deal to buy Soleno Therapeutics and its treatment for a rare, genetic form ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

By utilising augmented intelligence early, small and mid-sized companies can maximise their innovation potential, minimise ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, ...

Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...